We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RWE:XETRRWE AG Analysis

Data as of 2026-05-20 - not real-time

€56.44

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

RWE is trading at €56.44, comfortably above its 20‑day SMA of €58.90 and 50‑day SMA of €57.80, indicating a short‑term bullish bias, while the 200‑day SMA of €47.08 provides strong long‑term support. The RSI sits at 43, suggesting the stock is not yet oversold, and the MACD histogram remains negative, flagging potential downside pressure despite the overall bullish trend. Volatility over the past 30 days is elevated at roughly 28%, and the beta of 0.20 points to low market‑wide sensitivity, which together temper the upside potential.
Fundamentally, revenue has contracted by 33% and operating margins are negative, yet the company maintains a solid dividend yield of 2.13% with a modest payout ratio of 34%, supporting income‑focused investors. The DCF‑derived fair value of €53.10 lies below the current price, implying a modest overvaluation, but the consensus target price of €62‑63 suggests a potential upside of about 10%. Recent news highlights a profit drop that sparked market concern, while the latest earnings report was described as constructive, leaving the forward outlook mixed but cautiously optimistic.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support at €54.84
  • Negative MACD histogram indicating short‑term downside risk
  • Dividend yield providing income cushion

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Analyst consensus target price suggesting ~10% upside
  • Renewable energy transition driving future growth
  • Attractive dividend yield relative to sector peers

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strategic shift toward offshore/onshore wind and solar
  • Stable utilities sector with low beta and defensive characteristics
  • Long‑term cash generation potential despite current negative free cash flow

Key Metrics & Analysis

Financial Health

Revenue Growth-32.80%
Profit Margin14.51%
P/E Ratio17.3
ROE6.83%
ROA-0.42%
Debt/Equity57.29
P/B Ratio1.2
Op. Cash Flow€5.5B
Free Cash Flow€-10523374592
Industry P/E21.5

Technical Analysis

TrendBullish
RSI43.3
Support€54.84
Resistance€62.00
MA 20€58.90
MA 50€57.80
MA 200€47.08
MACDBearish
VolumeStable
Fear & Greed Index89.3

Valuation

Fair Value€53.10
Target Price€62.17
Upside/Downside10.16%
GradeFair
TypeValue
Dividend Yield2.13%

Risk Assessment

Beta0.20
Volatility28.29%
Sector RiskLow
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.